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have been recommended by NCCN guidelines. At the same time, we identified
many instances where the recommendations given by the NCCN guidelines have
not been endorsed by HZZO. CONCLUSIONS: Considering process related incon-
sistencies and consequential differences in reimbursement outcomes and patient
access to cancer drugs in Croatia compared, there is a strong need for the expedited
implementation of transparent HTA processes for cancer drugs. Multiple technol-
ogy assessments of the main indication groups and the highest cost drivers are
highly needed to ensure the full transparency of the reimbursement system and
the equity of patients’ access to the treatment options irrespectively of the disease.
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OBJECTIVES: Determine the impact of new end of life criteria on reimbursement
decisions of cancer drugs appraised by NICE. METHODS: Review of Single and
Multiple Technology Assessments on cancer treatments appraised by NICE from
January 2009 to April 2011. RESULTS:NICE appraised 30 cancer treatments. 16 were
recommended with restrictions and 13 were not recommended. The reason for not
recommending was poor cost effectiveness (7) and lack of evidence (6). The Com-
mittee considered the impact of giving a greater weight to QALYs achieved in the
later stages of terminal diseases in nine of the positive recommended drugs. End of
life criteria were considered when the most plausible ICERs fall above the threshold
normally considered as cost-effective. End of life criteria were not taken into ac-
count when the appraised drugs had ICERS below £30,000 per QALY gained (6 cases)
or when it resulted in cost saving for the NHS. When ICERs estimates exceeded
what NICE considers a reasonable use of NHS resources for the whole population
covered by the marketing authorisation the Committee discussed whether the
magnitude of weight required for the ICER to be in a cost effective range was
acceptable in special subgroups of population. CONCLUSIONS: The discussion of
end of life criteria was straight forward when the new drug provided a marked
change in the treatment of the disease or its high price was compensated by a
patient access scheme agreement. On contrary, it was more difficult to decide
whether survival benefits offered the extension of life required in order the sup-
plementary advice to be considered. The supplementary advice facilitated the ap-
praisal process of cancer drugs however the Committee had to make judgments to
interpret the incomplete evidence in order to decide what is good for patients and
who can benefit from new cancer treatments.
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OBJECTIVES: Reducing the burden of cancer through interventions based on clin-
ical trials remains an important strategy of oncology research. Public access to
information on clinical trials increases transparency of medical research and helps
patients to find information. The aim of this study was to investigate the number of
clinical trials in oncology carried out in Greece. METHODS: We searched the EU
Clinical Trials Register website. We analyzed the trends regarding the number of
approved by the National Organization for Medicines trials in a 7-year basis. We
also examined the number of trials by the type of cancer, the Phase and the status
of the trial and the trends in funding. In our survey we included only Phase II and
Phase III interventional trials, recruiting by adults and elderly, both men and
women, between 2004-2010. RESULTS: Greece ranks 14th among EU countries for
the clinical trials conducted in oncology, as 24,29% of all clinical trials carried out in
Greece concern cancer. Since 2004, 44 Phase II and 95 Phase III trials were approved,
the majority of which were related to target therapies of breast cancer (21.73%) and
non-small cell lung cancer (21.01%). 81.88% are still ongoing trials, 6.52% have been
completed while there is no feedback about the results. Finally, in Greece the main
sponsor in clinical research is industry (88.4%) while only 11.59% is funded by
research institutes. CONCLUSIONS: Although in Greece there is significant clinical
investigation in oncology, the need for the development of a new framework as
well as a well organized network that will inform key stakeholders, reduce bureau-
cracy and increase the number of clinical trials remains and calls for international
cooperation.
PCN180
THRESHOLD VALUES FOR COST-EFFECTIVENESS IN AHTAPOL AND NICE FOR
CANCER DRUG TECHNOLOGIES
Kiljan A, Kolasa K, Hermanowski T
Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland
OBJECTIVES: To identify empirical threshold values for cost-effectiveness on the
basis of past decisions in Agency for Health Technology Assessment (AHTAPol) in
Poland and National Institute for Health and Clinical Excellence (NICE) in the UK for
cancer drug technologies. METHODS: Review of recommendations issued by
AHTAPol and NICE for cancer drug technologies was performed. Period under in-
vestigation was August 2007 to March 2011 for AHTAPol and March 2000 – March
2011 for NICE. To identify empirical threshold values in both agencies, a compari-
son of ICER cost/QALY and past decisions was made. RESULTS: In the studied
period AHTAPol and NICE issued, respectively, 44 and 54 recommendations for
cancer drug technologies. Negative recommendations prevailed in Poland (43%).
Most common recommendations in NICE were positive recommendations with
major restriction (39%).The most commonly used measure of cost-effectiveness in
NICE was ICER cost/QALY (41 recommendations) while in Poland it was identified
only in 16 recommendations. As a result of a comparison of ICER cost/QALY and
past decisions empirical threshold values in both agencies were not identified. In
Poland four positive recommendations with restrictions and 9 negative ones were
placed above official AHTAPol’s threshold. In the same time, only 3 positive rec-
ommendations with or without restriction were below the threshold. In NICE, 17
positive recommendations with or without restrictions and 11 negative ones were
above the official threshold value of £30,000/QALY. Below this threshold, there
were 13 positive recommendations with or without restrictions. CONCLUSIONS:
AHTAPol, as well as NICE, don’t have definite empirical cost-effectiveness thresh-
old values for cancer drug technologies. The official threshold values set in both
agencies are not respected in the case of cancer drugs. Implementation of addi-
tional guidelines for “end-of-life” treatment in NICE may have potential impact on
decisions concerning cost-effectiveness of cancer drug technologies.
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OBJECTIVES: After marketing authorization, European HTA agencies may take
HRQoL data into account to support reimbursement. We want to explore here how
HRQoL have been included into HTA process and what their impact was on reim-
bursement decisions. METHODS: Initially, we’ve analyzed French HRQoL data on
oncology drugs to assess quality, type and impact of these data on the reimburse-
ment opinions made by the French National Autority (HAS). In the second stage, we
have performed a qualitative analysis to explore the main similarities and differ-
ences across HTA bodies in assessment of HRQoL to support reimbursement.
RESULTS: First stage: since 2008, 23 files were assessed by HAS. HRQoL data were
available for 11 oncology drugs; for 3 drugs HRQoL data were not taken into account
(open trial or missing data). For 5 drugs, no difference in HRQoL (on EORTC QLQ-
C30) was observed and in 3 cases, change in HRQoL might have had an impact on
final decisions.Second stage: more and more often HRQoL data are included into
files submitted for HTA and their quality is gradually improving over time. How-
ever, confusion still remains between functional measures and HRQoL. Some
countries only consider HRQoL data from randomised clinical trials. For other
countries, data from observational studies may also be of interest to provide addi-
tional information in real conditions of use. In addition, many countries consider
utility measures as one of HRQoL. In all cases, HRQoL remains a secondary end-
point in relative effectiveness assessment (REA) process. CONCLUSIONS: In Eu-
rope, the impact of HRQoL on reimbursement decisions could be enhanced if the
quality of data increases. Our analysis confirms the interest of the ongoing work on
the EUnetHTA guideline that should help assessors of European HTA agencies deal
with HRQoL and contribute to the harmonization of HRQoL definitions and use
across agencies.
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OBJECTIVES: Although prostate-specific antigen (PSA) screening is conducted
worldwide, its effectiveness in reducing mortality from prostate cancer has re-
mained controversial. In March 2009, intermediate results from the European Ran-
domized Study of Screening for Prostate Cancer (ERSPC) and the Prostate, Lung,
Colorectal and Ovarian (PLCO) Cancer Screening Trial were released. However, the
results of the two studies were inconsistent: the PLCO trial demonstrated no ben-
efits to screening, whereas the ERSPC study reported a 20% reduction in prostate
cancer mortality. We found and compared the assessment of the two RCTs in
guidelines, evidence reports and statements. METHODS: A search was performed
from March 2009 to May 2011 using MEDLINE, the Guideline International Network
library and the National Guidelines Clearinghouse to identify guidelines, evidence
reports and statements which have evaluated the two RCTs. Additional reports
recommended by experts were also included as needed. The changes in the revised
guidelines, evidence reports and statements were compared. RESULTS: Four
guidelines, two evidence reports and one statement matching our criteria were
found, but none contained any change in basic recommendation for PSA screening.
In addition, the American Society of Clinical Oncology evaluated the results of the
two studies in their review for major research in 2009. Although the American
Urological Association recommended PSA screening for men 40 years of age and
over, in other guidelines, PSA screening was not recommended for asymptomatic
persons. Most of the US reports were for opportunistic screening and pointed out
the necessity of shared decision-making for PSA screening. The European Urolog-
ical Association and the UK-NHS Cancer Screening Committee did not recommend
PSA for population-based screening. In contrast, the Japanese Urological Associa-
tion strongly recommended PSA screening in communities. CONCLUSIONS: Even
after the releases of two RCTs results, most reports have not revised their assess-
ment of PSA screening.
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